Pyoderma Gangrenosum disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

GARD: ¹⁹ Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, Crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. Each year in the United States, Pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with Pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy.

MalaCards based summary: Pyoderma Gangrenosum, also known as phagedenic pyoderma, is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and neutrophilic dermatosis, acute febrile. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are MIF Mediated Glucocorticoid Regulation and Integrin Pathway. The drugs Anti-Inflammatory Agents and Endothelial Growth Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and myeloid, and related phenotypes are fever and skin ulcer

Orphanet: ⁵⁸ Pyoderma gangrenosum (PG) is a primarily sterile inflammatory neutrophilic dermatosis characterized by recurrent cutaneous ulcerations with a mucopurulent or hemorrhagic exudate.

Wikipedia: ⁷⁵ Pyoderma gangrenosum is a rare, inflammatory skin disease where painful pustules or nodules become... more...

Sources

Related Diseases for Pyoderma Gangrenosum

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 827)

#	Related Disease	Score	Top Affiliating Genes
1	pyogenic sterile arthritis, pyoderma gangrenosum, and acne	33.1	PSTPIP1 NLRP3 MVK MEFV
2	neutrophilic dermatosis, acute febrile	31.9	TNF SIGLEC5 PSTPIP1 MEFV CXCL8 CSF3
3	inflammatory bowel disease 1	31.8	TNF NOD2 CCR6
4	crohn's disease	31.5	TNF SIGLEC5 NOD2 NLRP3 CXCL8 CCR6
5	ulcerative colitis	31.5	TNF NOD2 IL1R1 CXCL8 CCR6
6	fasciitis	31.4	TNF MMP1 CXCL8
7	necrotizing fasciitis	31.4	TNF F3 CXCL8
8	erythema nodosum	31.3	TNF NOD2 CXCL8
9	hidradenitis suppurativa	31.3	TNF PSTPIP1 NOD2 NLRP3 MEFV
10	hidradenitis	31.3	TNF PSTPIP1 NOD2 NLRP3 MEFV
11	vasculitis	31.3	TNF MEFV ITGB2 IFNA2 CXCL8 APOH
12	myelofibrosis	31.2	TNF IFNA2 CXCL8 CSF3
13	acne	31.1	TNF PSTPIP1 NLRP3 MMP1 MEFV CXCL8
14	colitis	31.1	TNF NOD2 IL1R1 CXCL8 CHI3L1 CCR6
15	erythema elevatum diutinum	31.0	PSTPIP1 CXCL8
16	myelodysplastic syndrome	31.0	TNF IFNA2 CXCL8 CSF3 CCR6
17	hypersensitivity vasculitis	31.0	TNF MEFV CCR6
18	polyarteritis nodosa	31.0	TNF MEFV ITGB2 IFNA2 APOH
19	polycythemia vera	30.9	TNF IFNA2 F3 CSF3
20	spondyloarthropathy 1	30.9	TNF NOD2 IL1R1 CCR6
21	pouchitis	30.9	TNF NOD2
22	antiphospholipid syndrome	30.9	TNF F3 APOH
23	purpura	30.8	TNF F3 CXCL8 APOH
24	granulomatous dermatitis	30.8	TNF NOD2
25	cholangitis	30.8	TNF NOD2 F3 CXCL8
26	diverticulitis	30.7	TNF MMP9 CCR6
27	chronic recurrent multifocal osteomyelitis	30.7	TNF PSTPIP1 NOD2 NLRP3 MEFV
28	enterocolitis	30.7	TNF NOD2 CXCL8
29	neutropenia	30.7	TNF IFNA2 CXCL8 CSF3
30	decubitus ulcer	30.7	TNF MMP9 CXCL8
31	aortitis	30.7	TNF CSF3 CCR6
32	autoimmune disease	30.6	TNF MMP9 F3 CCR6 APOH
33	scleritis	30.6	TNF MMP9 ITGB2 CCR6
34	synovitis	30.6	TNF MMP9 MMP1 CXCL8
35	erysipelas	30.6	TNF PSTPIP1 MVK MEFV
36	fungal infectious disease	30.6	TNF CXCL8 CSF3 CCR6
37	cholangitis, primary sclerosing	30.6	TNF NOD2 CXCL8 CCR6
38	toxic shock syndrome	30.6	TNF IL1R1 F3 CXCL8 CSF3
39	cyclic neutropenia	30.6	TNF CXCL8 CSF3
40	chronic ulcer of skin	30.6	TNF MMP9 MMP1 CXCL8
41	osteomyelitis	30.5	TNF NOD2 NLRP3 MMP1 MEFV CXCL8
42	psoriasis	30.5	TNF NOD2 ITGB2 IL1R1 CXCL8 CCR6
43	diarrhea	30.5	TNF NOD2 MVK IFNA2 CXCL8 CSF3
44	sarcoidosis 1	30.5	TNF NOD2 CHI3L1 CCR6
45	spondylitis	30.5	TNF NOD2 CHI3L1 CCR6
46	deficiency anemia	30.5	TNF IFNA2 F3 CSF3 CCR6
47	autoinflammatory syndrome	30.5	NOD2 NLRP3 MVK MEFV
48	mucormycosis	30.5	TNF CSF3 CCR6
49	hepatitis a	30.5	TNF IFNA2 F3
50	inguinal hernia	30.5	MMP9 MMP1 F3

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:

Sources

Symptoms & Phenotypes for Pyoderma Gangrenosum

Human phenotypes related to Pyoderma Gangrenosum:

⁵⁸ ³⁰ (show all 16)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	fever ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001945
2	skin ulcer ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0200042
3	arthralgia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002829
4	myalgia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003326
5	papule ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0200034
6	myositis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100614
7	inflammation of the large intestine ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002037
8	myelodysplasia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002863
9	pustule ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0200039
10	atrophic scars ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001075
11	rheumatoid arthritis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001370
12	myeloid leukemia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012324
13	increased circulating antibody level ³⁰	Frequent (33%)		HP:0010702
14	skin vesicle ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0200037
15	abnormal blistering of the skin ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0008066
16	increased antibody level in blood ⁵⁸		Frequent (79-30%)

GenomeRNAi Phenotypes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.19	APOH CCR6 CHI3L1 CSF3 CXCL8 F3
2	no effect	GR00402-S-2	10.19	APOH CCR6 CHI3L1 CSF3 F3 IFNA2

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.86	CCR6 CHI3L1 CSF3 F3 IFNA2 IL1R1
2	hematopoietic system	MP:0005397	9.47	CCR6 CHI3L1 CSF3 F3 IFNA2 IL1R1

Sources

Drugs & Therapeutics for Pyoderma Gangrenosum

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Anti-Inflammatory Agents

Phase 4

2

Endothelial Growth Factors

Phase 4

3

Mitogens

Phase 4

4

Adalimumab

Approved, Experimental

Phase 3

331731-18-1

5

Antirheumatic Agents

Phase 3

6

Pharmaceutical Solutions

Phase 3

7

Ixekizumab

Approved, Investigational

Phase 2

1143503-69-8

8

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Synonyms:

1,2-Dehydrocortisone

1,4-Pregnadiene-17a,21-diol-3,11,20-trione

1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione

1,4-Pregnadiene-17α,21-diol-3,11,20-trione

17,21-Dihydroxypregna-1,4-diene-3,11,20-trione

Acis brand OF prednisone

Acsis, prednison

Adasone

Ancortone

Apo-prednisone

Apotex brand OF prednisone

Aventis brand OF prednisone

Betapar

Bicortone

Cartancyl

Colisone

Cortan

Cortancyl

Cortidelt

Cotone

Cutason

Dacorten

Dacortin

Decortancyl

Decortin

Decortisyl

Dehydrocortisone

Dekortin

Delcortin

Dellacort

Dellacort A

Delta Cortelan

Delta E

Delta-cortelan

Deltacortene

delta-Cortisone

Deltacortisone

Deltacortone

Delta-cortone

DELTA-DOME

Deltasone

Deltison

Deltisona

Deltisone

Deltra

Diadreson

Di-Adreson

Diba brand OF prednisone

Econosone

Encorton

Encortone

Enkortolon

Enkorton

Fawns and mcallan brand OF prednisone

FERNISONE

Ferring brand OF prednisone

Fiasone

GALENpharma brand OF prednisone

Halsey drug brand OF prednisone

Hexal brand OF prednisone

Hoechst brand OF prednisone

Hostacortin

ICN brand OF prednisone

Incocortyl

In-Sone

Juvason

Kortancyl

Lichtenstein brand OF prednisone

Liquid pred

Lisacort

LODOTRA

Lodotra®|Sterapred®

Me-Korti

Merck brand OF prednisone

Merz brand OF prednisone

Metacortandracin

Meticorten

Mibe brand OF prednisone

Nisona

Nizon

Novoprednisone

NSC-10023

Nurison

Orasone

Origen Prednisone

Panafcort

Panasol

PARACORT

Parmenison

Pehacort

Pharmacia brand OF prednisone

PRD

Precort

Predeltin

PREDN

Predni tablinen

PREDNICEN-M

Prednicorm

Prednicort

Prednicot

Prednidib

Prednilonga

Predniment

Prednison

Prednison acsis

Prednison galen

Prednison hexal

Prednisona

Prednisona [INN-Spanish]

Prednisone

PREDNISONE INTENSOL

PREDNISONE TABLETS

Prednisonum

Prednisonum [INN-Latin]

Prednitone

Prednizon

Prednovister

Presone

Pronison

Pronisone

RAYOS

Rectodelt

Retrocortine

Schering-plough brand OF prednisone

Seatrace brand OF prednisone

SERVISONE

Solvay brand OF prednisone

Sone

Sterapred

Supercortil

Trommsdorff brand OF prednisone

Ultracorten

Ultracortene

Winpred

Wojtab

Zenadrid

9

Vilobelimab

Investigational

Phase 2

2250440-41-4

10

Dermatologic Agents

Phase 2

11

Complement System Proteins

Phase 2

12

Immunosuppressive Agents

Phase 2

13

Infliximab

Approved

170277-31-3

14

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

133585-56-5, 60-18-4, 556-02-5

1153 6057

Synonyms:

(-)-a-Amino-p-hydroxyhydrocinnamate

(-)-a-Amino-p-hydroxyhydrocinnamic acid

(-)-alpha-Amino-p-hydroxyhydrocinnamate

(-)-alpha-Amino-p-hydroxyhydrocinnamic acid

(-)-Α-amino-p-hydroxyhydrocinnamate

(−)-α-amino-p-hydroxyhydrocinnamic acid

(-)-Α-amino-p-hydroxyhydrocinnamic acid

(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate

(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid

(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID

(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID

(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid

(R)-3-(p-Hydroxyphenyl)alanine

(S)-(-)-Tyrosine

(S)-2-Amino-3-(p-hydroxyphenyl)propionate

(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid

(S)-3-(p-Hydroxyphenyl)alanine

(S)-a-Amino-4-hydroxybenzenepropanoate

(S)-a-Amino-4-hydroxy-benzenepropanoate

(S)-a-Amino-4-hydroxybenzenepropanoic acid

(S)-a-Amino-4-hydroxy-benzenepropanoic acid

(S)-alpha-Amino-4-hydroxybenzenepropanoate

(S)-alpha-Amino-4-hydroxy-benzenepropanoate

(S)-alpha-amino-4-Hydroxybenzenepropanoic acid

(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid

(S)-Tyrosine

(S)-Α-amino-4-hydroxybenzenepropanoate

(S)-α-amino-4-hydroxybenzenepropanoic acid

2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate

2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid

2-Amino-3-(4-hydroxyphenyl)propanoate

2-Amino-3-(4-hydroxyphenyl)propanoic acid

2-Amino-3-(p-hydroxyphenyl)propionate

2-Amino-3-(p-hydroxyphenyl)propionic acid

3-(4-Hydroxyphenyl)-L-alanine

3-(p-Hydroxyphenyl)alanine

4-hydroxy-L-phenylalanine

6-Hydroxysandoricin

Benzenepropanoate

Benzenepropanoic acid

D-Tyr

D-Tyrosin

FEMA NO. 3736

L Tyrosine

LEVODOPA IMPURITY, L-TYROSINE-

LEVODOPA RELATED COMPOUND L-TYROSINE

L-p-Tyrosine

L-Tyrosin

L-tyrosine

Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid

NSC-82624

Para tyrosine

Para-tyrosine

p-Tyrosine

Tirosina

Tyr

Tyrosin

Tyrosine

Tyrosine, L isomer

Tyrosine, L-isomer

Tyrosinum

Y

15

Gastrointestinal Agents

16

Immunoglobulins, Intravenous

Early Phase 1

17

Antineoplastic Agents, Immunological

Early Phase 1

Interventional clinical trials:

(show all 23)

#	Name	Status	NCT ID	Phase	Drugs
1	A Novel Therapeutic Treatment of Pyoderma Gangrenosum	Recruiting	NCT05120726	Phase 4
2	A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan	Completed	NCT03311464	Phase 3	adalimumab
3	Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum As a New Treatment Strategy	Not yet recruiting	NCT05343754	Phase 3	Hyperbaric oxygen
4	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Terminated	NCT02315417	Phase 3	gevokizumab;Placebo;gevokizumab open-label
5	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Terminated	NCT02326740	Phase 3	gevokizumab;Placebo;gevokizumab open-label
6	A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum	Terminated	NCT02318914	Phase 3	gevokizumab
7	Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum	Unknown status	NCT02733094	Phase 1, Phase 2	Secukinumab
8	An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum	Completed	NCT01882504	Phase 2	gevokizumab
9	A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum	Completed	NCT01965613	Phase 2
10	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Completed	NCT03137160	Phase 2
11	Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)	Completed	NCT03971643	Phase 2	IFX-1
12	A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum	Completed	NCT01302795	Phase 2	Canakinumab
13	Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Recruiting	NCT04901325	Phase 2	Baricitinib
14	A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum	Terminated	NCT03072953	Phase 2	APD334
15	The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Withdrawn	NCT04274166	Phase 2	secukinumab 150 mg (2 injections per dose
16	A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)	Withdrawn	NCT00690846	Phase 2	adalimumab
17	Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	Withdrawn	NCT00730717	Phase 2	Humira
18	Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015	Unknown status	NCT03636737
19	Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses	Unknown status	NCT01952275
20	An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum	Completed	NCT00791557		Infliximab
21	Post-marketing Observational Study for Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)	Recruiting	NCT04750213
22	Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma	Active, not recruiting	NCT04895566	Early Phase 1
23	Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy	Not yet recruiting	NCT04792957

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Clofazimine

SULFAPYRIDINE PWDR

Cochrane evidence based reviews: pyoderma gangrenosum

Sources

Genetic Tests for Pyoderma Gangrenosum

Sources

Anatomical Context for Pyoderma Gangrenosum

Organs/tissues related to Pyoderma Gangrenosum:

MalaCards : Skin, Bone, Myeloid, Neutrophil, Breast, Endothelial, Spleen

Sources

Publications for Pyoderma Gangrenosum

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 3577)

#	Title	Authors	PMID	Year
1	Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene. ⁵³ ⁶²	Hong JB...Chiu HC	19700023	2009
2	Pyrin Modulates the Intracellular Distribution of PSTPIP1. ⁵³ ⁶²	Waite AL...Gumucio DL	19584923	2009
3	PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. ⁵³ ⁶²	Veillette A...Davidson D	19290936	2009
4	The inherited autoinflammatory syndrome: a decade of discovery. ⁵³ ⁶²	Goldfinger S	19768193	2009
5	Autoinflammatory diseases: clinical and genetic advances. ⁵³ ⁶²	Farasat S...Toro JR	18347298	2008
6	Autoinflammatory gene mutations in Behçet's disease. ⁵³ ⁶²	Kone-Paut I...Touitou I	17213252	2007
7	The systemic autoinflammatory diseases: inborn errors of the innate immune system. ⁵³ ⁶²	Brydges S...Kastner DL	16724804	2006
8	Autoinflammatory syndromes. ⁵³ ⁶²	Galeazzi M...Doria A	16466630	2006
9	Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. ⁵³ ⁶²	Stichweh DS...Pascual V	15916580	2005
10	A common pathway in periodic fever syndromes. ⁵³ ⁶²	McDermott MF	15324736	2004
11	CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. ⁵³ ⁶²	Newman B...Siminovitch KA	15102098	2004
12	Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. ⁶²	Gibson LE	35599359	2022
13	Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine. ⁶²	Franceschi J...Milpied B	35771124	2022
14	[Clinical analysis of 49 cases of non-inflammasome related conditions]. ⁶²	Zhang CH...Song HM	36444428	2022
15	Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database. ⁶²	Hillen JB...Pratt N	35933497	2022
16	Neutrophilic dermatoses. ⁶²	Delaleu J...Bouaziz JD	35870984	2022
17	Successful treatment of pyoderma gangrenosum using adalimumab in a patient undergoing hemodialysis. ⁶²	Seishima M...Sugie S	35862244	2022
18	A Case of Post-caesarean Pyoderma Gangrenosum. ⁶²	Bal H...Lal S	36457428	2022
19	Improvement of refractory pyoderma gangrenosum with adjunctive maggot debridement therapy. ⁶²	Dozier L...Kerdel F	36468819	2022
20	Treatment of pyoderma gangrenosum with apremilast monotherapy. ⁶²	Bordeaux ZA...West CE	36345410	2022
21	Pyoderma Gangrenosum after COVID-19 Infection and Vaccination. ⁶²	Zou H...Daveluy S	36442730	2022
22	Characterization of Legal Claims Involving Patients with Pyoderma Gangrenosum. ⁶²	Pfeifer HJ...Ortega Loayza AG	35895601	2022
23	Pyoderma Gangrenosum Affecting the Dorsal Hand: A Case Report. ⁶²	Haase LR...Bafus BT	36337430	2022
24	Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: A retrospective study. ⁶²	Reese AM...Ortega-Loayza AG	35151756	2022
25	[Development of spindle cell squamous cell carcinoma within a longstanding pyoderma gangrenosum]. ⁶²	Drexler K...Karrer S	35471236	2022
26	Clinical efficacy of flap transplantation combined with vacuum sealing drainage and methylprednisolone and cyclosporine in the treatment of pyoderma gangrenosum. ⁶²	Hao Y...Feng Z	36321334	2022
27	Peristomal granulation tissue mimicking peristomal pyoderma gangrenosum in the context of urine-diverting ostomies. ⁶²	McLarney BD...Hsu S	36186406	2022
28	A Rare Complication: Postoperative Pyoderma Gangrenosum in Segmental Colitis Associated With Diverticulosis. ⁶²	Dunleavy K...Pardi D	36001403	2022
29	Pyoderma Gangrenosum. ⁶²	Zhou HY...Liu ZH	36351270	2022
30	Juvenile gangrenous vasculitis of the scrotum: systematic review. ⁶²	Bazzi N...Moussa M	35323998	2022
31	Brocq's geometric phagedena over penis with keloidal scars. ⁶²	A S...Jayaraman J	36220799	2022
32	Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum. ⁶²	Acierno S...Giani T	36004431	2022
33	Pyoderma Gangrenosum Triggered by COVID-19 Vaccination in a Patient with Ulcerative Colitis: A Case Report. ⁶²	Kim YC...Park YJ	36426538	2022
34	A case with prediagnosis of soft tissue infection who finally diagnosed as pyoderma gangrenosum of ulcerative colitis. ⁶²	Duzenli T	36412491	2022
35	Skin Manifestations in Patients with Selective Immunoglobulin E Deficiency. ⁶²	Picado C...Mascaro JM	36431272	2022
36	Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review. ⁶²	Mital R...Kaffenberger BH	36434425	2022
37	Limb amputation in patients with pyoderma gangrenosum: a multi-institutional case series. ⁶²	Shakshouk H...Ortega-Loayza AG	36446938	2022
38	Clinical characteristics of peristomal pyoderma gangrenosum: A Single Center Retrospective Observational Study. ⁶²	Honma M...Tani C	35789032	2022
39	Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome associated with pyoderma gangrenosum: report of two patients. ⁶²	Ma M...Li C	36345566	2022
40	A Rare Form of Granulomatosis With Polyangiitis With Pyoderma Gangrenosum. ⁶²	Samardzic T...Felek S	36407211	2022
41	Abscess-like skin and lung lesions in a patient with acute lymphoblastic leukemia: Pyoderma gangrenosum. ⁶²	Akyol S...Oren H	35278042	2022
42	Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis. ⁶²	Klumpp A...Schepler H	36097621	2022
43	Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review. ⁶²	Diab R...Mirzaei HR	35946554	2022
44	The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum. ⁶²	Rick J...Ortega-Loayza AG	36305958	2022
45	Off-label uses of ustekinumab. ⁶²	Ye L...Wang L	36208443	2022
46	Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum. ⁶²	Ozeki K...Kataoka H	35643412	2022
47	An unusual presentation of celiac disease in adult patient. ⁶²	Frioui R...Hammami H	36245465	2022
48	Pyoderma gangrenosum-like ulcers over the face in a case of granulomatosis with polyangiitis. ⁶²	Kanan K...Patra S	36250767	2022
49	Postherpetic Trigeminal Trophic Syndrome: A Case Report. ⁶²	Lee JH...Lee SK	36198630	2022
50	The role of interleukins 6, 8, 17 and 23 in the pathogenesis of pyoderma gangrenosum. ⁶²	Rubas K...Maj J	36268700	2022

Sources

Genes for Pyoderma Gangrenosum

Genes related to Pyoderma Gangrenosum (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PSTPIP1	Proline-Serine-Threonine Phosphatase Interacting Protein 1	Protein Coding	39.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	19700023 15916580 17213252 (more) 15102098 19290936 19584923
2	MEFV	MEFV Innate Immunity Regulator, Pyrin	Protein Coding	33.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	18347298 19768193 16724804 (more) 16466630 15324736
3	NOD2	Nucleotide Binding Oligomerization Domain Containing 2	Protein Coding	20.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15102098 16466630
4	NLRP3	NLR Family Pyrin Domain Containing 3	Protein Coding	15.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17213252 16466630
5	TNF	Tumor Necrosis Factor	Protein Coding	15.34	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	MVK	Mevalonate Kinase	Protein Coding	14.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17213252 16466630
7	CSF3	Colony Stimulating Factor 3	Protein Coding	14.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	14.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	IL1R1	Interleukin 1 Receptor Type 1	Protein Coding	13.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	MMP9	Matrix Metallopeptidase 9	Protein Coding	12.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	ITGB2	Integrin Subunit Beta 2	Protein Coding	12.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	APOH	Apolipoprotein H	Protein Coding	11.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	F3	Coagulation Factor III, Tissue Factor	Protein Coding	11.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	MMP10	Matrix Metallopeptidase 10	Protein Coding	11.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	MMP26	Matrix Metallopeptidase 26	Protein Coding	11.17	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	MMP1	Matrix Metallopeptidase 1	Protein Coding	10.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	IFNA2	Interferon Alpha 2	Protein Coding	8.32	GeneCards inferred via : Publications (show sections)
18	CHI3L1	Chitinase 3 Like 1	Protein Coding	7.98	GeneCards inferred via : Publications (show sections)
19	SIGLEC5	Sialic Acid Binding Ig Like Lectin 5	Protein Coding	7.02	DISEASES inferred ¹⁴ ¹⁴
20	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	6.93	DISEASES inferred ¹⁴ ¹⁴
21	LPIN2	Lipin 2	Protein Coding	6.78	DISEASES inferred ¹⁴
22	IL1B	Interleukin 1 Beta	Protein Coding	6.51	DISEASES inferred ¹⁴
23	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	6.51	DISEASES inferred ¹⁴

Sources

Variations for Pyoderma Gangrenosum

Sources

Expression for Pyoderma Gangrenosum

Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Sources

Pathways for Pyoderma Gangrenosum

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 29)

#	Super pathways	Score	Top Affiliating Genes
1	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.55	TNF MMP9 MMP1 IL1R1 IFNA2 CXCL8
2	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.32	MMP9 MMP26 MMP10 MMP1 ITGB2 CXCL8
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.17	TNF NOD2 MMP9 MMP1 ITGB2 IL1R1
4	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.05	TNF SIGLEC5 PSTPIP1 NOD2 NLRP3 MMP9
5	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.34	TNF NOD2 NLRP3 IL1R1 IFNA2 CXCL8
6	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.21	TNF MMP9 MMP1 CXCL8 CSF3
7	Spinal cord injury ⁷⁴	11.93	TNF MMP9 IL1R1 CXCL8
8	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways ⁶⁶ Show member pathways NOD1/2 Signaling Pathway ⁶⁶	11.81	PSTPIP1 NOD2 NLRP3 MEFV
9	CCL18 signaling pathway ⁷⁴	11.8	ITGB2 CXCL8 CCR6
10	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.75	CXCL8 ITGB2 MMP1 MMP9 TNF
11	Innate Lymphoid Cells Differentiation ⁶⁵	11.71	TNF IL1R1 CCR6
12	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.7	TNF NLRP3 F3
13	Matrix metalloproteinases ⁷⁴ Show member pathways Activation of Matrix Metalloproteinases ⁶⁶ Inhibition of Matrix Metalloproteinases ⁶⁴	11.65	TNF MMP9 MMP26 MMP10 MMP1
14	AP-1 transcription factor network ⁶¹	11.63	MMP9 MMP1 CXCL8
15	Lung fibrosis ⁷⁴	11.61	CSF3 CXCL8 MMP9 TNF
16	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.6	CXCL8 MMP1 MMP9 TNF
17	Cell adhesion_ECM remodeling ²²	11.56	MMP9 MMP10 MMP1 CXCL8
18	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.47	TNF NOD2 IFNA2 CXCL8
19	Nucleotide-binding oligomerization domain (NOD) pathway ⁷⁴	11.39	MEFV NLRP3 NOD2
20	Interleukin-10 signaling ⁶⁶	11.38	TNF IL1R1 CXCL8 CSF3
21	Bladder cancer ⁷⁴	11.37	MMP9 MMP1 CXCL8
22	Validated transcriptional targets of AP1 family members Fra1 and Fra2 ⁶¹	11.3	MMP9 MMP1 CXCL8
23	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.23	TNF MMP1 CXCL8
24	Burn wound healing ⁷⁴	11.23	TNF MMP9 MMP1 IFNA2 CXCL8
25	amb2 Integrin signaling ⁶¹	11.2	TNF MMP9 ITGB2
26	IL1 and megakaryocytes in obesity ⁷⁴	11.1	NLRP3 MMP9 IL1R1
27	Prostaglandin signaling ⁷⁴	10.9	TNF NLRP3 MMP9 CXCL8
28	Mammary gland development pathway - Involution (Stage 4 of 4) ⁷⁴	10.62	MMP9 CHI3L1
29	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.3	TNF CXCL8

Sources

GO Terms for Pyoderma Gangrenosum

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular matrix	GO:0031012	9.81	MMP9 MMP26 MMP10 MMP1 CHI3L1
2	cell surface	GO:0009986	9.77	TNF NOD2 ITGB2 IL1R1 F3 CCR6
3	extracellular region	GO:0005576	9.7	APOH CHI3L1 CSF3 CXCL8 F3 IFNA2

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of protein kinase B signaling	GO:0051897	10.14	CHI3L1 CSF3 F3 TNF
2	extracellular matrix organization	GO:0030198	10.13	MMP1 MMP10 MMP26 MMP9 TNF
3	cellular response to lipopolysaccharide	GO:0071222	10.11	TNF NOD2 NLRP3 CXCL8 CSF3
4	negative regulation of inflammatory response	GO:0050728	10.09	NLRP3 MVK MMP26 MEFV
5	extracellular matrix disassembly	GO:0022617	10.05	MMP9 MMP10 MMP1
6	regulation of inflammatory response	GO:0050727	10.05	TNF NOD2 NLRP3 IL1R1
7	positive regulation of interleukin-8 production	GO:0032757	10.01	TNF NOD2 F3 CHI3L1
8	positive regulation of interleukin-1 beta production	GO:0032731	9.97	TNF NOD2 NLRP3 MEFV
9	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	9.87	TNF NOD2
10	positive regulation of type 2 immune response	GO:0002830	9.86	NOD2 NLRP3
11	positive regulation of prostaglandin-E synthase activity	GO:2000363	9.8	NOD2 ITGB2
12	cellular response to peptidoglycan	GO:0071224	9.76	NOD2 NLRP3
13	leukocyte migration involved in inflammatory response	GO:0002523	9.72	TNF ITGB2 CCR6
14	detection of biotic stimulus	GO:0009595	9.65	NOD2 NLRP3
15	pattern recognition receptor signaling pathway	GO:0002221	9.65	NOD2 NLRP3 MEFV
16	defense response	GO:0006952	9.63	CXCL8 IFNA2 NLRP3 NOD2 TNF
17	inflammatory response	GO:0006954	9.58	TNF PSTPIP1 NLRP3 MEFV ITGB2 IL1R1
18	collagen catabolic process	GO:0030574	9.56	MMP9 MMP26 MMP10 MMP1
19	cellular extravasation	GO:0045123	9.52	TNF ITGB2

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	metalloendopeptidase activity	GO:0004222	9.56	MMP9 MMP26 MMP10 MMP1
2	metallopeptidase activity	GO:0008237	9.02	MMP9 MMP26 MMP10 MMP1

Sources

Sources for Pyoderma Gangrenosum

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: PYD001 MIFTS: 55	Pyoderma Gangrenosum Categories: Bone diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Pyoderma Gangrenosum

Aliases & Classifications for Pyoderma Gangrenosum

MalaCards integrated aliases for Pyoderma Gangrenosum:

Characteristics:

Prevelance:

Age Of Onset:

Classifications:

External Ids:

Summaries for Pyoderma Gangrenosum

Related Diseases for Pyoderma Gangrenosum

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:

Symptoms & Phenotypes for Pyoderma Gangrenosum

Human phenotypes related to Pyoderma Gangrenosum:

GenomeRNAi Phenotypes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

Drugs & Therapeutics for Pyoderma Gangrenosum

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

Anatomical Context for Pyoderma Gangrenosum

Organs/tissues related to Pyoderma Gangrenosum:

Publications for Pyoderma Gangrenosum

Articles related to Pyoderma Gangrenosum:

Genes for Pyoderma Gangrenosum

Genes related to Pyoderma Gangrenosum (0 elite genes):

Variations for Pyoderma Gangrenosum

Expression for Pyoderma Gangrenosum

Pathways for Pyoderma Gangrenosum

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

GO Terms for Pyoderma Gangrenosum

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

Sources for Pyoderma Gangrenosum

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :